2015

Elucidation of the correlation between genotype and clinical behavior in meningeal SFT/HPC

Bijdrage Stichting STOPhersentumoren.nl: 6.987,75- euro uit bestemmingsfonds Meningeomen per 1 november 2015

Lees meer...

Determining blood-brain barier penetration of R428, for use in the treatment of diffuse intrinsic pontine glioma (DIPG)

Bijdrage Stichting STOPhersentumoren.nl: 15.100,- euro uit bestemmingsfonds Kinderhersentumoren per 1 november 2015

Lees meer...

Polymersomes for local delivery of radionuclides and/or targeted agents to high grade brain tumours

Bijdrage Stichting STOPhersentumoren.nl: 120.987,- euro per 1 november 2015

Lees meer...

T-Cell Therapy for Low-Grade Gliomas

Bijdrage Stichting STOPhersentumoren.nl: 90.000,- euro per 1 november 2015

Lees meer...

From 'sweet' to treat; elucidating the immune-evasive role of sialic acid sugars and their receptors in malignant glioma'

Bijdrage Stichting STOPhersentumoren.nl: 148.092,- euro per 1 november 2015

Lees meer...

The high grade glioma synergy atlas: Tailored cocktails selected by computational connectivity mapping

Bijdrage Stichting STOPhersentumoren.nl: 36.000,- euro per 1 november 2015

Lees meer...

Blood-based diagnosis and monitoring of ‘lower-grade gliomas’ to predict malignant progression and optimize treatment

Bijdrage Stichting STOPhersentumoren.nl: 60.000,- euro per 1 november 2015

Lees meer...

Preclinical analysis of a highly promising TMZ sensitizer in molecularly defined glioblastoma subtypes: The novel GPCR inhibitor R243

Bijdrage Stichting STOPhersentumoren.nl: 42.000,- euro per 1 november 2015

Lees meer...

Identification of effective compounds targeting IDH-‐1 mutant glioma using novel patient-‐derived preclinical models

Bijdrage Stichting STOPhersentumoren.nl: 106.500,- euro per 1 november 2015

Lees meer...

Tackling glioblastoma therapy resistance via exploitation of novel genetic concepts

Bijdrage Stichting STOPhersentumoren.nl: 125.000,- euro per 1 november 2015

Lees meer...

A phase I trial for the addition of chloroquine, an autophagy inhibitor, to concurrent chemoradiation for newly diagnosed glioblastoma: the follow-up of a preclinical project funded by “Stichting Stop Hersentumoren"

Bijdrage Stichting STOPhersentumoren.nl: 45.854,- euro per 1 november 2015

Lees meer...

Determining blood-brain barier penetration of R428, for use in the treatment of diffuse intrinsic pontine glioma (DIPG) (2)

Bijdrage Stichting STOPhersentumoren.nl: 15.100,- euro uit bestemmingsfonds Kinderhersentumoren per 1 november 2015

Lees meer...

Onderzoek

Aantal uitgekeerde subsidies:

57

2015

Elucidation of the correlation between genotype and clinical behavior in meningeal SFT/HPC

Determining blood-brain barier penetration of R428, for use in the treatment of diffuse intrinsic pontine glioma (DIPG)

Polymersomes for local delivery of radionuclides and/or targeted agents to high grade brain tumours

T-Cell Therapy for Low-Grade Gliomas

From 'sweet' to treat; elucidating the immune-evasive role of sialic acid sugars and their receptors in malignant glioma'

The high grade glioma synergy atlas: Tailored cocktails selected by computational connectivity mapping

Blood-based diagnosis and monitoring of ‘lower-grade gliomas’ to predict malignant progression and optimize treatment

Preclinical analysis of a highly promising TMZ sensitizer in molecularly defined glioblastoma subtypes: The novel GPCR inhibitor R243

Identification of effective compounds targeting IDH-‐1 mutant glioma using novel patient-‐derived preclinical models

Tackling glioblastoma therapy resistance via exploitation of novel genetic concepts

A phase I trial for the addition of chloroquine, an autophagy inhibitor, to concurrent chemoradiation for newly diagnosed glioblastoma: the follow-up of a preclinical project funded by “Stichting Stop Hersentumoren"

Determining blood-brain barier penetration of R428, for use in the treatment of diffuse intrinsic pontine glioma (DIPG) (2)

Onderzoek overzicht

Wij gaan voor de beste kwaliteit!

Ons fonds

Externe Links

Contact

Volg ons

Samen verschil maken in hersentumor onderzoek!